{"id":784743,"date":"2023-09-18T18:03:10","date_gmt":"2023-09-18T22:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/"},"modified":"2023-09-18T18:03:10","modified_gmt":"2023-09-18T22:03:10","slug":"catalent-appoints-david-mcerlane-as-biologics-segment-leader","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/","title":{"rendered":"Catalent Appoints David McErlane as Biologics Segment Leader"},"content":{"rendered":"

<\/p>\n

\nCatalent Appoints David McErlane as Biologics Segment Leader<\/p>\n

SOMERSET, N.J.–(BUSINESS WIRE<\/a>)–
\nCatalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent\u2019s Biologics segment, effective September 25, 2023.<\/p>\n

\nMr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza\u2019s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor\u2019s degree in electronic systems engineering from Glasgow Caledonian University.<\/p>\n

\n\u201cDavid is a seasoned and highly successful business leader with a record of developing winning strategies that drive growth and create significant value,\u201d said Alessandro Maselli, President and Chief Executive Officer of Catalent. \u201cI am excited to work with David, who I am confident will make an immediate, positive impact on our Biologics business and help take Catalent to its next phase of growth.\u201d<\/p>\n

\nMr. McErlane will lead all of Catalent\u2019s Biologics businesses and global service offerings \u2013 including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.<\/p>\n

\nAbout Catalent, Inc.<\/p>\n

\nCatalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent\u2019s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year. For more information, visit www.catalent.com<\/a>.<\/p>\n

\nMore products. Better treatments. Reliably supplied.\u2122<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230918343681\/en\/<\/a><\/span><\/p>\n

\nInvestor Contact:
\n
Paul Surdez
\n
(732) 537-6325
\n
investors@catalent.com
\n<\/a><\/p>\n

Media Contact:
\n
Bernie Clark
\n
+1 (732) 537-6400
\n
media@catalent.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America New Jersey<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Technology Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Catalent Appoints David McErlane as Biologics Segment Leader SOMERSET, N.J.–(BUSINESS WIRE)– Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent\u2019s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza\u2019s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor\u2019s degree in electronic systems engineering from Glasgow Caledonian University. \u201cDavid is a seasoned and highly successful business leader with a record of developing winning … <\/p>\n

Continue reading “Catalent Appoints David McErlane as Biologics Segment Leader”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-784743","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCatalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Catalent Appoints David McErlane as Biologics Segment Leader SOMERSET, N.J.–(BUSINESS WIRE)– Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent\u2019s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza\u2019s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor\u2019s degree in electronic systems engineering from Glasgow Caledonian University. \u201cDavid is a seasoned and highly successful business leader with a record of developing winning … Continue reading "Catalent Appoints David McErlane as Biologics Segment Leader"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-18T22:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Catalent Appoints David McErlane as Biologics Segment Leader\",\"datePublished\":\"2023-09-18T22:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/\",\"name\":\"Catalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-09-18T22:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalent Appoints David McErlane as Biologics Segment Leader\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/","og_locale":"en_US","og_type":"article","og_title":"Catalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk","og_description":"Catalent Appoints David McErlane as Biologics Segment Leader SOMERSET, N.J.–(BUSINESS WIRE)– Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent\u2019s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza\u2019s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor\u2019s degree in electronic systems engineering from Glasgow Caledonian University. \u201cDavid is a seasoned and highly successful business leader with a record of developing winning … Continue reading \"Catalent Appoints David McErlane as Biologics Segment Leader\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-18T22:03:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Catalent Appoints David McErlane as Biologics Segment Leader","datePublished":"2023-09-18T22:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/","name":"Catalent Appoints David McErlane as Biologics Segment Leader - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-09-18T22:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230918343681r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalent-appoints-david-mcerlane-as-biologics-segment-leader\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Catalent Appoints David McErlane as Biologics Segment Leader"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=784743"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784743\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=784743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=784743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=784743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}